Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,440.76 23.08 0.16%
TOPIX 1,168.76 2.21 0.19%
HANG SENG 22,787.51 91.50 0.40%

Mark McDonough to Assume CEO Role at CombiMatrix



Mark McDonough to Assume CEO Role at CombiMatrix

Veteran Sales and Diagnostic Executive to Succeed R. Judd Jessup, Who Will
Retire in March

IRVINE, Calif., Feb. 22, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for cancer and developmental disorders, today announced that Mark
McDonough, currently the Company's Chief Commercial Officer, will become Chief
Executive Officer following the retirement of CEO R. Judd Jessup, who has
announced his retirement, effective March 15, 2013.

McDonough, a resident of San Diego, came to CombiMatrix in 2012 with more than
15 years of experience in sales and business development with a specialty in
diagnostics. McDonough previously worked for Fortune 500 companies (EMC and
Lab Corp) as well as successful emerging companies (Ventana Medical Systems)
and startups (Pathwork Diagnostics).

Jessup was named CEO in 2010 when CombiMatrix was in the midst of a transition
phase from a manufacturing company to a diagnostics lab and services
organization. Jessup recently refocused CombiMatrix's commercial efforts on
prenatal and pediatric testing in response to the growing demand for molecular
diagnostic testing in those specialties. Part of that strategic and
operational shift included the recruitment of McDonough last year to lead the
Company's commercial efforts.

"In his time at CombiMatrix, McDonough, (age 43), has been responsible for
building a robust sales structure to accommodate the new strategic focus and
effectively transitioning, equipping and training that team," Jessup said. "We
brought Mark in to build and lead our sales team and he has done everything we
expected and more. My role at Combimatrix was to lead during the transition to
a pure-play diagnostics lab. With that transition complete, we have now
refocused the organization on key markets where we are seeing rapid growth and
Mark has led that execution over the past eight months. I believe the Company
is headed in the right direction, is building momentum and is in very capable
hands."

For four years before joining CombiMatrix last August, McDonough was Vice
President, Sales, Customer Service and Training at Redwood City, CA-based
Pathwork Diagnostics.  He grew sales each year in that role, served on the
executive steering committee and was actively involved in all strategic
commercial initiatives.

"This is a tremendous opportunity for me to lead a Company that we believe is
well-positioned with a broad opportunity for success," McDonough said. "We
have a focused strategy and are building a talented, experienced sales and
marketing team. At this point, it's all about execution in the coming periods
and continuing to ramp the prenatal testing business. If we continue to
execute as we have in recent months, we believe CombiMatrix will gain more
market share, capitalize on markets that are now trending in our direction
and, importantly, grow shareholder value."

Prior to Pathwork, from 2002-2008, McDonough worked for Irvine, CA-based
USLabs/Dianon (when USLabs was acquired by LabCorp) and ultimately became Vice
President of Sales. During his time there, he led a 56-member sales team, led
various sales and marketing initiatives and helped drive a turnaround effort
during a management overhaul.

McDonough received a Bachelor's Degree in Finance from Miami University in
Oxford, Ohio.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets. The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies. CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals. Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not limited to,
statements regarding projected results of operations and management's future
business, operational and strategic plans, momentum of our pre-natal and
pediatric businesses, test menu expansion, services and reports development
and attracting greater prenatal genetic screening business. These
forward-looking statements are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties referred to above
include, but are not limited to: our ability to gain more market share,
capitalize on markets and grow shareholder value; our ability to successfully
expand the base of our customers and strategic partners, add to the menu of
our diagnostic tests in both of our primary markets, develop and introduce new
tests and related reports, optimize the reimbursements received for our
testing services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to successfully
accelerate sales, steadily increase the size of our customer rosters in both
developmental medicine and oncology; lack of growth in the developmental
markets; our ability to attract and retain a qualified sales force; rapid
technological change in our markets; changes in demand for our future
products; the ability of microarray technology to become the standard of care;
legislative, regulatory and competitive developments; general economic
conditions; and various other factors. Further information on potential
factors that could affect our financial results is included in our Annual
Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with
the Securities and Exchange Commission. We undertake no obligation to revise
or update publicly any forward-looking statements for any reason, except as
required by law.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement